We proposed an 11 platelet-gene panel (CD79B, CSDE1, IL-32, ITGA2B, LUC7L, NDUFAB1, RBM6, SKAP2, SS18L2, TRAF3IP3, and ZNF195) that provides reliable and economically viable platelet-based classification between cancer and healthy samples. This evidence concerns the gene RBM6 and cancer.